MedImmune Reaches for a Blockbuster
MedImmune Inc. is reaching for a blockbuster through its acquisition of Aviron, whose nasally inhaled flu vaccine FluMist now seems close to winning FDA approval--perhaps in time for the 2002 flu season. Aviron has struggled to develop the product, particularly with regulatory and marketing issues that MedImmune has shown it can handle well.
You may also be interested in...
The once clear distinction between discovery-based biotechs and specialty in-licensing companies is dissolving, as emphasis increases on ability to deliver margins and growth. Cephalon's acquisition of France's Group Lafon, for example, gives Cephalon--for a steep price--a foothold in one of Europe's largest markets, sales and marketing infrastructure, and the opportunity to capture hefty royalties that Cephalon has been paying to Lafon for rights to a key product.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.